PMID: 11921421Mar 29, 2002Paper

Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria

Diabetes/metabolism Research and Reviews
Kathryn C B TanKaren S L Lam

Abstract

Microalbuminuria is associated with dysfunction of the vascular endothelium in patients with diabetes mellitus. The objective of the present study was to determine whether treatment with losartan at a dose sufficient to lower urinary albumin excretion was accompanied by an improvement in endothelial function in type 2 diabetic patients with microalbuminuria. Endothelial function was measured in 80 type 2 diabetic patients with microalbuminuria and 68 non-diabetic controls using high-resolution vascular ultrasound. The diabetic patients were randomised to receive either losartan 50 mg daily or placebo in a 6-month double-blind study. Urinary albumin excretion and endothelial function were assessed at baseline, 3 and 6 months. Both endothelium-dependent (p<0.01) and -independent vasodilation (p<0.01) were significantly impaired in diabetic patients with or without history of hypertension compared to the non-diabetic controls. At baseline, the losartan- and placebo-treated groups were comparable in their clinical characteristics. Blood pressure did not change significantly in either group throughout the study. Urinary mean albumin excretion rate (MAER) decreased in the losartan-treated group (p<0.01) whereas an increase was observ...Continue Reading

References

Feb 9, 1984·The New England Journal of Medicine·C E Mogensen
May 1, 1995·European Heart Journal·W Auch-SchwelkE Fleck
Jan 1, 1993·European Journal of Clinical Pharmacology·W K ChanJ A Critchley
Jan 1, 1996·Kidney & Blood Pressure Research·K F Hilgers, J F Mann
Apr 1, 1997·Cardiovascular Research·C D StehouwerV W van Hinsbergh
Aug 1, 1997·Scandinavian Journal of Clinical and Laboratory Investigation·F S NielsenH H Parving
Jun 12, 1998·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·G Wolf
Aug 5, 1998·International Journal of Clinical & Laboratory Research·S NeriD Ierna
Mar 11, 1999·The American Journal of Cardiology·K K KohR O Cannon
Oct 8, 1999·The Journal of Clinical Investigation·Y TsutsumiT Iwasaka
Nov 5, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·D R MeekingK M Shaw
Feb 2, 2000·Current Opinion in Nephrology and Hypertension·R T Gansevoort, D de Zeeuw
Sep 6, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·J CollisD Green
Nov 18, 2000·Journal of the American College of Cardiology·C CheethamD Green
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group

❮ Previous
Next ❯

Citations

Aug 13, 2003·Current Atherosclerosis Reports·Richard J MacIsaac, Mark E Cooper
Sep 10, 2003·Best Practice & Research. Clinical Endocrinology & Metabolism·Hannele Yki-Järvinen
Mar 5, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Ausilia MaioneGiovanni F M Strippoli
May 23, 2012·International Journal of Vascular Medicine·Gopi Krishna KolluruChristopher G Kevil
Jul 28, 2006·Kidney International·P Ruggenenti, G Remuzzi
Jul 17, 2010·Mediators of Inflammation·Inge A M van den OeverSuat Simsek
May 18, 2016·Journal of Physical Therapy Science·Ahmad H AlghadirEinas Al-Eisa
Jul 1, 2004·Expert Review of Cardiovascular Therapy·Norberto PericoGiuseppe Remuzzi
Apr 20, 2004·Current Opinion in Nephrology and Hypertension·Richard J MacIsaacMark E Cooper
Jan 27, 2018·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Shalini Jamwal, Saurabh Sharma
Jun 24, 2006·Journal of Cardiovascular Pharmacology·Peter OchodnickyDick de Zeeuw
Apr 28, 2010·Journal of Cardiovascular Pharmacology·Wing Tak WongYu Huang
Jan 22, 2019·Current Medicinal Chemistry·Anastasios TentolourisNikolaos Tentolouris
Feb 4, 2014·American Journal of Physiology. Heart and Circulatory Physiology·Modar KassanKhalid Matrougui
Oct 2, 2020·Kidney International·UNKNOWN Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group
Jun 2, 2021·Clinical and Experimental Pharmacology & Physiology·Do Young KimHyun Sook Hong

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association
G N ThomasJ C N Chan
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme
K T PreissnerH P Hammes
© 2022 Meta ULC. All rights reserved